Circulating tumor DNA may be a prognostic biomarker for relapse and early recurrence detection in resected early-stage ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...

Nubeqa Plus ADT Effective in mHSPC Regardless of Disease Volume ...

New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and ...

Living with follicular lymphoma, I challenge common misconceptions about cancer, highlighting the unique and varied ...

Among patients with early-stage triple-negative breast cancer, a beneficial pathologic complete response rate was higher in ...

New advancements in cancer treatment are reducing the need for radical surgeries, offering organ-sparing therapies and enhancing survivorship care and support for patients.

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical ...

The FDA granted its first approval for a systemic therapy for patients with non-small cell lung cancer with an Neuregulin 1 ...

The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer ...

An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung ...

As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung cancer research. This optimism comes in the wake of the Food and Drug Administration’s ...